(Q30353176)

20 June 2017

1 reference

title

Effects of PPARalpha on cardiac glucose metabolism: a transcriptional equivalent of the glucose-fatty acid cycle? (English)

1 reference

20 June 2017

0 references

0 references

Brian N Finck

1

1 reference

20 June 2017

publication date

1 March 2006

1 reference

Expert Review of Cardiovascular Therapy

20 June 2017

published in

1 reference

20 June 2017

volume

4

1 reference

20 June 2017

issue

2

1 reference

20 June 2017

page(s)

161-171

1 reference

Global and societal implications of the diabetes epidemic

20 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Peroxisome proliferator-activated receptors: nuclear control of metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Effect of BM 17.0744, a PPARalpha ligand, on the metabolism of perfused hearts from control and diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Less extrahepatic induction of fatty acid beta-oxidation enzymes by PPAR alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

A potential link between muscle peroxisome proliferator- activated receptor-alpha signaling and obesity-related diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts can be rescued by increasing glucose transport and utilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

A role for peroxisome proliferator-activated receptor alpha (PPARalpha ) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated wi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Peroxisome proliferator-activated receptor delta activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Regulation of muscle fiber type and running endurance by PPARdelta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Peroxisome proliferator-activated receptor beta/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

PPAR gamma is required for placental, cardiac, and adipose tissue development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Peroxisome proliferator-activated receptors in inflammation control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Induction of IκBα Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor-α Activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

PPAR delta: an uncompletely known nuclear receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Roles of peroxisome proliferator-activated receptor delta in skeletal muscle function and adaptation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Peroxisome proliferator-activated receptor beta/delta as a therapeutic target for metabolic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

PPARdelta is a very low-density lipoprotein sensor in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Transcriptional repression of atherogenic inflammation: modulation by PPARdelta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Central role of the adipocyte in the insulin-sensitising and cardiovascular risk modifying actions of the thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Adiponectin: a relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Treatment of type 2 diabeticdb/dbmice with a novel PPARγ agonist improves cardiac metabolism but not contractile function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Peroxisome proliferator-activated receptors gamma ligands and ischemia and reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Deleterious effects of acute treatment with a peroxisome proliferator-activated receptor-gamma activator in myocardial ischemia and reperfusion in pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Nonhypoglycemic effects of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Fluid retention mediated by renal PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

G-protein signaling participates in the development of diabetic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

PPAR-alpha activation required for decreased glucose uptake and increased susceptibility to injury during ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Myocyte enhancer factor 2 (MEF2)-binding site is required for GLUT4 gene expression in transgenic mice. Regulation of MEF2 DNA binding activity in insulin-deficient diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Role of AMP--activated protein kinase in the control of glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

The AMP-activated protein kinase cascade--a unifying system for energy control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Free fatty acids repress the GLUT4 gene expression in cardiac muscle via novel response elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.161

21 January 2018

Identifiers

DOI

10.1586/14779072.4.2.161

1 reference

20 June 2017

1 reference